EventsMOL2NET'21, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 7th ed.
Event submissions
Published
with-doi10.3390/mol2net-07-11615
This submission belongs to the session 02. CHEMBIO.ORG-07: Org. Chem., Med. Chem., Mol. Biol., & Pharm. Industry Congress, Paris, France-Galveston, USA, 2021. of the event MOL2NET'21, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 7th ed.
Published date
10 Nov, 2021
Academic Editor
author-avatarSonia Arrasate Gil
Citation
Li Chen, Bairong Shen, Javier Meana, Cost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With EGFR Mutations In China, in Proceedings of MOL2NET'21, Conference on Molecular, Biomed., Comput. & Network Science and Engineering, 7th ed., 25 January–30 December 2021, MDPI: Basel, Switzerland, doi: 10.3390/mol2net-07-11615
Share
Email
Facebook
Twitter
LinkedIn

Cost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With EGFR Mutations In China

Li Chen 1,2
Javier Meana 3
Bairong Shen 4
1. 1.University of the Basque Country UPV/EHU
2. 2.West China 2nd University Hospital,SCU
3. University of the Basque Country UPV/EHU, 48940, Leioa, Biscay, Basque Country, Spain
4. Institutes for Systems Genetics, West China Hospital, SCU
Abstract

Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib plus chemotherapy (GCP) versus gefitinib alone for advanced non–small-cell lung (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations in China.

Methods: A decision-analytic Markov model was conducted to simulate the disease process of advanced NSCLC patients with EGFR mutations. Three distinct health states: progression-free survival (PFS), progressive disease (PD) and death were included. Clinical data were derived from the NEJ009 Study. The cost was evaluated from the perspective of the Chinese society. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICER) were calculated over a 10-year lifetime horizon. One-way sensitivity analysis and probabilistic sensitivity analysis were also performed to explore the uncertainty of parameters in the study.

Results: The base case analysis demonstrated that gefitinib plus chemotherapy gained 2.44 QALYs at an average cost of $59,571.34, while the effectiveness and cost of gefitinib group were 1.82 QALYs and $52,492.75, respectively. The ICER for gefitinib plus chemotherapy was $11,499.98 per QALY gained. The ICER was lower than the accepted willingness-to-pay (WTP) threshold, which was three times gross domestic product (GDP) per capita of China ($31,498.70 per QALY). Variation of parameters did not reversal the cost-effectiveness of gefitinib plus chemotherapy through univariable and probabilistic sensitivity analyses.

Conclusion: Our results showed that gefitinib plus chemotherapy is a cost-effective treatment option compared with gefitinib for advanced NSCLC patients with EGFR mutations in China.

Keywords
cost-effectiveness
gefitinib
NSCLC
EGFR
Markov model
Manuscript
NSCLC-cost-effec.pdf
Using TCGAbiolinks package in ranking breast cancer genes from The Cancer Genome Atlas (TCGA) to predict disease-associated genes
Eye Disorders Associated with newer Antiepileptic drugs: A real-world disproportionality analysis of FDA Adverse Reporting System events